Search - tctmd.com

Displaying 741 - 760 of 1207

Sort: Relevancy | Date

News Conference News TCT 2015

FDA Speaker Outlines a Novel Vision for Device Regulation

October 13, 2015

News Conference News TCT 2015

Robotic Systems to Play Greater Role in Cath Lab of the Future

Todd Neale

October 12, 2015

News Conference News TCT 2015

LAA Closure Trials Illustrate Evolution of Devices, Trial Design

October 12, 2015

News Conference News TCT 2015

ABSORB III: Novel Bioresorbable Scaffold as Good as Standard-of-Care DES

Yael L. Maxwell

October 12, 2015

News Industry News

ABSORB III: Clinical Trial Demonstrates That A Bioresorbable Scaffold Is Non-Inferior To A Drug-Eluting Stent In Patients With Coronary Artery Disease

October 12, 2015

News Opinion Fellow Talk

Researcher Much? A Brief Review of TCT’s Clinical Trial Design and Interpretation Sessions

October 11, 2015

News Conference News TCT 2015

Use of LAA Occlusion in Low-Risk Patients Debated

Todd Neale

October 11, 2015

News Conference News TCT 2015

Experts Debate Optimal Pharmacologic Approach for STEMI Patients

October 11, 2015

News Daily News

Reduced Leaflet Motion in Bioprosthetic Aortic Valves Not Uncommon But Remedied by Anticoagulation

L.A. McKeown

October 08, 2015

News Industry News

Boston Scientific Announces Scheduled Presentations At TCT 2015

October 08, 2015

News Industry News

Silk Road Medical Announces First U.S. Commercial Case with the ENROUTE® Transcarotid Stent System

October 07, 2015

News Daily News

在PCI患者中切入部位和坎格雷洛之间没有相互作用

Caitlin E. Cox

October 06, 2015

News Industry News

SurModics Receives FDA IDE Approval for Early Feasibility Study of the SurVeil™ Drug-Coated Balloon

October 06, 2015

News Daily News

No Interplay Between Access Site, Cangrelor Effects in PCI Patients

Caitlin E. Cox

October 06, 2015

News Daily News

No hay interacción entre el punto de acceso y los efectos del Cangrelor en pacientes con PCI

Caitlin E. Cox

October 06, 2015

News Industry News

Boston Scientific Receives FDA Approval For SYNERGY™ Bioabsorbable Polymer Drug-Eluting Stent System

October 05, 2015

News Industry News

Neuravi Announces European Launch of Innovative Minimally Invasive Stroke Therapy

October 01, 2015

News Daily News

In the Early Days of TAVR, No Mortality Penalty for Patients Treated Outside of Trial Centers

October 01, 2015

News Industry News

Intact Vascular Announces Conditional FDA Approval for Tack Optimized Balloon Angioplasty II (TOBA II) Study and Enrollment of First Patients

September 30, 2015

News Industry News

CHMP grants positive opinion for idarucizumab, the specific reversal agent for dabigatran etexilate (Pradaxa®)

September 25, 2015

Advertisement

FDA Speaker Outlines a Novel Vision for Device Regulation

Robotic Systems to Play Greater Role in Cath Lab of the Future

LAA Closure Trials Illustrate Evolution of Devices, Trial Design

ABSORB III: Novel Bioresorbable Scaffold as Good as Standard-of-Care DES

ABSORB III: Clinical Trial Demonstrates That A Bioresorbable Scaffold Is Non-Inferior To A Drug-Eluting Stent In Patients With Coronary Artery Disease

Researcher Much? A Brief Review of TCT’s Clinical Trial Design and Interpretation Sessions

Use of LAA Occlusion in Low-Risk Patients Debated

Experts Debate Optimal Pharmacologic Approach for STEMI Patients

Reduced Leaflet Motion in Bioprosthetic Aortic Valves Not Uncommon But Remedied by Anticoagulation

Boston Scientific Announces Scheduled Presentations At TCT 2015

Silk Road Medical Announces First U.S. Commercial Case with the ENROUTE® Transcarotid Stent System

在PCI患者中切入部位和坎格雷洛之间没有相互作用

SurModics Receives FDA IDE Approval for Early Feasibility Study of the SurVeil™ Drug-Coated Balloon

No Interplay Between Access Site, Cangrelor Effects in PCI Patients

No hay interacción entre el punto de acceso y los efectos del Cangrelor en pacientes con PCI

Boston Scientific Receives FDA Approval For SYNERGY™ Bioabsorbable Polymer Drug-Eluting Stent System

Neuravi Announces European Launch of Innovative Minimally Invasive Stroke Therapy

In the Early Days of TAVR, No Mortality Penalty for Patients Treated Outside of Trial Centers

Intact Vascular Announces Conditional FDA Approval for Tack Optimized Balloon Angioplasty II (TOBA II) Study and Enrollment of First Patients

CHMP grants positive opinion for idarucizumab, the specific reversal agent for dabigatran etexilate (Pradaxa®)

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content